ArticleAging cell2025
Single-Cell Sequencing Reveals That CD4
Abstract read
In one paragraph
Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia.Experimental & molecular medicine · 2026Article
- Immune surveillance and immune evasion of senescent cells.Nature reviews. Immunology · 2026Review
- Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries.npj aging · 2026Article
- Spatial and single-cell transcriptomics reveal a HIF-1α/NF-κB-driven hypoxia-induced senescence axis in BPH epithelium.International journal of biological sciences · 2026Article
- Benign Uroandrological Ecosystem: A Thorough Overview from Single-Cell and Spatial Transcriptomics.Research (Washington, D.C.) · 2026Review
- Nanomedicine for Benign Prostatic Hyperplasia: Pathological Axes and Translational Evidence.International journal of nanomedicine · 2026Review
- Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Zheng LiDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0002-0584-1808
Xiaofei WangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Zhifu LiuDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0002-6659-1814
Senmao LiDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0003-0377-8566
Zhenan ZhangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Chenchen HuangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0002-3595-1688
Yixiao LiuDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0002-5386-8175
Xingxing TangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Jiaen ZhangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Peimin ZhouDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Ying GanDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0001-8393-6768
Yu FanDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0003-3743-3988
Yisen MengDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Kaiwei YangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Shuai HuDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.
Qian ZhangDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0001-9009-2997
Wei YuDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male), molecular Diagnosis and Treatment Center, National Research Center for Genitourinary Oncology, Beijing, China.ORCID 0000-0002-0938-0308
Funding
Beijing Natural Science Foundation 7232179Beijing Natural Science Foundation - Youth Program 7244424First-Class Discipline Team of Kunming Medical University 2024XKTDYS03Foundation of Kunming Medical University Second Affiliated Hospital 2024BS08Guangdong Basic and Applied Basic Research Foundation 2023A1515010128National Natural Science Foundation of China (NSFC) 82072826National Natural Science Foundation of China (NSFC) 82273151National Natural Science Foundation of China (NSFC) 82300871Natural Science Foundation of Ningxia Hui Autonomous Region 2024AAC03738
Abstract
Benign prostatic hyperplasia (BPH) is an age-related condition characterized by progressive prostate enlargement driven in part by the accumulation of senescent epithelial cells and their pro-inflammatory secretome. Using human single-cell RNA sequencing and laser capture microdissection, we identified C-X-C Motif Chemokine Ligand 13 (CXCL13) as a key chemokine secreted by senescent prostate epithelial cells. CXCL13 recruits CD4
Indexed as
CD4-Positive T-LymphocytesCellular SenescenceProstateProstatic HyperplasiaSingle-Cell AnalysisAnimalsChemokine CXCL13Disease ProgressionEpithelial CellsEpitheliumHumansMaleMiceChemokine CXCL13BPHCD4+ CTLcellular senescenceCXCL13single‐cellTreg
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.